Schedule of computation of basic and diluted net (loss)/income per share |
The following table sets forth the computation of basic and diluted net (loss)/income per share for the three months and nine months ended September 30, 2023, and 2022 (in thousands, except number of shares): | | | | | | | | | | | | | | | Three months ended September 30, | | Nine months ended September 30, | | | 2023 | | | 2022 | | 2023 | | 2022 | Numerator: | | | | | | | | | | | | | Net (loss)/income | | $ | (14,110) | | $ | 8,221 | | $ | (56,157) | | $ | 26,484 | Net loss attributable to noncontrolling interest | | | 38 | | | 21 | | | 103 | | | 47 | Net (loss)/income attributable to Barinthus Bio shareholders | | $ | (14,072) | | $ | 8,242 | | $ | (56,054) | | $ | 26,531 | Denominator: | | | | | | | | | | | | | Weighted-average ordinary shares outstanding, basic | | | 38,533,833 | | | 37,247,123 | | | 38,320,208 | | | 37,213,787 | Effect of dilutive stock options | | | — | | | 909,441 | | | — | | | 1,012,304 | Weighted-average ordinary shares outstanding, diluted | | | 38,533,833 | | | 38,156,564 | | | 38,320,208 | | | 38,226,092 | Net (loss)/income per share attributable to ordinary shareholders, basic | | $ | (0.37) | | $ | 0.22 | | $ | (1.46) | | $ | 0.71 | Net (loss)/income per share attributable to ordinary shareholders, diluted | | $ | (0.37) | | $ | 0.22 | | $ | (1.46) | | $ | 0.69 |
|